Table 2 Status of different Smac mimetics

AZD5582

–

Pre-clinical

–

APG-1387

(SM-1387)

NCT03386526

Phase I

Advanced Solid Tumors or Hematologic Malignancies

NCT03585322

Phase I

Chronic Hepatitis B

ASTX660

NCT04155580

Phase I

Relapsed/Refractory Acute Myeloid Leukemia

NCT02503423

Phase I/II

Advanced Solid Tumors and Lymphomas

Birinapant

(TL32711)

NCT02587962

Phase I/II

Solid Tumors

NCT00993239

Phase I

(Completed)

Refractory Solid Tumors or Lymphoma

NCT01188499

Phase I

(Completed)

Advanced or Metastatic Solid Tumors

NCT01940172

Phase I

(Completed)

Relapsed Ovarian Cancer

NCT01573780

Phase I

(Terminated – safety unrelated issue)

Advanced Solid Tumors

NCT01681368

Phase II

(Terminated – lack of a clinical benefit)

Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Debio 1143

(AT-406, SM-406)

NCT04122625

Phase I

Solid Tumor

NCT03270176

Phase I

Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

NCT03871959

Phase I

Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma

NCT02022098

Phase I/II

Squamous Cell Carcinoma of the Head and Neck

NCT01078649

Phase I

(Completed)

Advanced Solid Tumors and Lymphomas

GDC-0152

NCT00977067

Phase I

(Terminated – safety unrelated issue)

Locally Advanced or Metastatic Malignancies

LCL161

NCT02649673

Phase I

Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

NCT03111992

Phase I

Multiple Myeloma

NCT01968915

Phase I

(Completed)

Advanced Solid Tumors

NCT02098161

Phase II

Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT01955434

Phase II

(Completed)

Relapsed or Refractory Multiple Myeloma

WX20120108

–

Pre-clinical

–